New insights into the clinical evaluation of hereditary transthyretin amyloidosis patients: a single center's experience [0.03%]
遗传性转甲状腺素蛋白淀粉样变性患者的临床评估新见解：一家中心的经验
Ole B Suhr,Sandra Gustavsson,Victoria Heldestad et al.
Ole B Suhr et al.
Over the last decade, new medical treatment modalities have emerged based on increased insights into amyloid formation. With the increased possibilities for treatment of amyloidosis caused by transthyretin (TTR) amyloid deposits comes the n...
Krista Farrell,Roger A Barker
Krista Farrell
Currently the mainstay of Parkinson's disease (PD) therapy is the pharmacological replacement of the loss of the dopaminergic nigrostriatal pathway using drugs such as dopamine agonists and levodopa. Whilst these drugs effectively ameliorat...
Malin Wennström,Henrietta M Nielsen
Malin Wennström
Cell adhesion molecules (CAMs) mediate interactions between cells and their surroundings that are vital to processes controlling for cell survival, activation, migration, and plasticity. However, increasing evidence suggests that CAMs also ...
Nataša Klepac,Mario Habek,Ivan Adamec et al.
Nataša Klepac et al.
In the text that follows, we review the main clinical features, genetic characteristics, and treatment options for Parkinson's disease (PD), considering the age at onset. The clinical variability between patients with PD points at the exist...
Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets [0.03%]
多发性硬化症患者的步行功能障碍-延释盐酸达非那新片的新治疗策略及临床潜力
Herbert R Henney rd,Andrew R Blight
Herbert R Henney rd
Walking impairment is a clinical hallmark of multiple sclerosis (MS) that has been under-recognized as a therapeutic target for pharmacologic intervention. The development and approval of dalfampridine extended release tablets (dalfampridin...
Rohit Aggarwal,Chester V Oddis
Rohit Aggarwal
The idiopathic inflammatory myopathies are a heterogeneous group of diseases that include dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and other less common myopathies. These are clinically and histopathologically ...
Update on pediatric dystonias: etiology, epidemiology, and management [0.03%]
儿科扭转痉挛的最新研究：病因、流行病学和治疗措施
Emilio Fernández-Alvarez,Nardo Nardocci
Emilio Fernández-Alvarez
Dystonia is a movement disorder characterized by sustained muscle contractions producing twisting, repetitive, and patterned movements or abnormal postures. Dystonia is among the most commonly observed movement disorders in clinical practic...
Emerging oral immunomodulating agents - focus on teriflunomide for the treatment of multiple sclerosis [0.03%]
用于治疗多发性硬化的新型口服免疫调节药物：特立氟胺的临床应用
Enyioma Nwankwo,Douglas R Allington,Michael P Rivey
Enyioma Nwankwo
Treatment for multiple sclerosis (MS), a chronic disease of the central nervous system, has historically relied exclusively on the use of injectable therapies. As the disease requires lifelong therapy, the development of oral therapies that...
William F Kaemmerer,Richard C Grondin
William F Kaemmerer
Therapies targeting mutant huntingtin DNA, mRNA, and protein have a chance at becoming the first disease-modifying treatments for Huntington's disease, a fatal inherited neurodegenerative disorder for which only symptom management treatment...
Multimodal intervention improves fatigue and quality of life in subjects with progressive multiple sclerosis: a pilot study [0.03%]
多模态干预改善进行性多发性硬化患者的疲劳和生活质量：一项试点研究
Babita Bisht,Warren G Darling,E Torage Shivapour et al.
Babita Bisht et al.
Background: Fatigue is a disabling symptom of multiple sclerosis (MS) and reduces quality of life. The aim of this study was to investigate the effects of a multimodal intervention, including a modified Paleolithic diet, ...